(Total Views: 597)
Posted On: 08/20/2019 8:54:22 AM
Post# of 30066
No change in the no of outstanding shares from last 1st quarter and a new subsidiary formed to around PhenoGuard:
"As of June 30, 2019 the number of shares outstanding of our Common Stock was: 261,384,788
As of June 30, 2019, the number of shares outstanding of our Common Stock was: 261,384,788
As of March 31, 2019, the number of shares outstanding of our Common Stock was: 261,384,788"
"Trimeric Labs, Inc. thatis further exploiting the neurotrophic factor discovery platform “PhenoGuard” from which MANF was discovered. Trimeric is seeking to discover additional neurotrophic factors from PhenoGuard as potential treatments for Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, ALS, and other neurological conditions;"
"As of June 30, 2019 the number of shares outstanding of our Common Stock was: 261,384,788
As of June 30, 2019, the number of shares outstanding of our Common Stock was: 261,384,788
As of March 31, 2019, the number of shares outstanding of our Common Stock was: 261,384,788"
"Trimeric Labs, Inc. thatis further exploiting the neurotrophic factor discovery platform “PhenoGuard” from which MANF was discovered. Trimeric is seeking to discover additional neurotrophic factors from PhenoGuard as potential treatments for Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, ALS, and other neurological conditions;"
(3)
(0)
